MA44082A - Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation - Google Patents

Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation

Info

Publication number
MA44082A
MA44082A MA044082A MA44082A MA44082A MA 44082 A MA44082 A MA 44082A MA 044082 A MA044082 A MA 044082A MA 44082 A MA44082 A MA 44082A MA 44082 A MA44082 A MA 44082A
Authority
MA
Morocco
Prior art keywords
immunoreactivity
ctla
methods
bispecific molecules
bispecific
Prior art date
Application number
MA044082A
Other languages
English (en)
Inventor
Ezio Bonvini
Gurunadh Reddy Chichili
Leslie S Johnson
Scott Koenig
Motte-Mohs Ross La
Paul A Moore
Kalpana Shah
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of MA44082A publication Critical patent/MA44082A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA044082A 2015-12-14 2016-12-12 Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation MA44082A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562266944P 2015-12-14 2015-12-14

Publications (1)

Publication Number Publication Date
MA44082A true MA44082A (fr) 2018-10-24

Family

ID=59057441

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044082A MA44082A (fr) 2015-12-14 2016-12-12 Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation

Country Status (26)

Country Link
US (3) US10954301B2 (fr)
EP (1) EP3389714A4 (fr)
JP (2) JP6955507B2 (fr)
KR (1) KR102424513B1 (fr)
CN (1) CN108367069B (fr)
AR (1) AR107781A1 (fr)
AU (2) AU2016370376B2 (fr)
BR (1) BR112018011781A2 (fr)
CA (1) CA3006462C (fr)
CL (1) CL2018001545A1 (fr)
CO (1) CO2018005932A2 (fr)
CR (1) CR20180318A (fr)
EA (1) EA201891178A1 (fr)
EC (1) ECSP18043564A (fr)
GE (1) GEP20217328B (fr)
HK (1) HK1255039A1 (fr)
IL (1) IL260021B (fr)
MA (1) MA44082A (fr)
MX (1) MX2018007089A (fr)
MY (1) MY196756A (fr)
PH (1) PH12018501220A1 (fr)
SG (1) SG11201804839WA (fr)
TW (2) TW202208440A (fr)
UA (1) UA125611C2 (fr)
WO (1) WO2017106061A1 (fr)
ZA (1) ZA201803472B (fr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108368170B (zh) 2015-07-13 2022-04-15 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
CA3132021C (fr) 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Liants de pd1 et/ou lag3
EP3377527A1 (fr) 2015-11-18 2018-09-26 Merck Sharp & Dohme Corp. Liants ctla4
CA3007030A1 (fr) 2015-12-07 2017-06-15 Xencor, Inc. Anticorps heterodimees se liant a cd3 et psma
TW202208440A (zh) 2015-12-14 2022-03-01 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
EP3432924A1 (fr) * 2016-03-23 2019-01-30 Novartis AG Mini-corps sécrétés par des cellules et leurs usages
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
AR108377A1 (es) * 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
CA3026151A1 (fr) 2016-06-14 2017-12-21 Xencor, Inc. Anticorps inhibiteurs de points de controle bispecifiques
WO2018035710A1 (fr) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anticorps anti-ctla4
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
JP7258747B2 (ja) 2016-10-28 2023-04-17 ブリストル－マイヤーズ スクイブ カンパニー 抗ｐｄ－１抗体を用いた尿路上皮癌の処置方法
PE20191131A1 (es) 2016-11-03 2019-09-02 Bristol Myers Squibb Co Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos
WO2018089293A2 (fr) * 2016-11-08 2018-05-17 Qilu Puget Sound Biotherapeutics Corporation Anticorps anti-pd1 et anti-ctla4
US20210101980A1 (en) 2017-03-31 2021-04-08 Bristol-Myers Squibb Company Methods of treating tumor
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
US11723975B2 (en) 2017-05-30 2023-08-15 Bristol-Myers Squibb Company Compositions comprising an anti-LAG-3 antibody or an anti-LAG-3 antibody and an anti-PD-1 or anti-PD-L1 antibody
EP3630842A2 (fr) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprenant une combinaison d'un anticorps anti-lag-3, d'un inhibiteur de voie pd-1 et d'un agent immunothérapeutique
AU2018277824A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Treatment of LAG-3 positive tumors
EP3630840A1 (fr) 2017-06-01 2020-04-08 Bristol-Myers Squibb Company Méthodes de traitement d'une tumeur au moyen d'un anticorps anti-pd-1
US11421029B2 (en) 2017-09-01 2022-08-23 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Recombinant bispecific antibodies to PD-L1 and CTLA-4
KR20200074137A (ko) 2017-10-10 2020-06-24 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
WO2019075468A1 (fr) 2017-10-15 2019-04-18 Bristol-Myers Squibb Company Procédés de traitement de tumeur
KR20200091382A (ko) * 2017-11-02 2020-07-30 시스트이뮨, 인코포레이티드 이중특이성 항체 및 이의 제조 및 사용 방법
WO2019090330A1 (fr) 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Méthodes de traitement d'une tumeur
CN112272563A (zh) * 2017-11-08 2021-01-26 Xencor股份有限公司 使用新颖抗pd-1序列的双特异性和单特异性抗体
WO2019143607A1 (fr) 2018-01-16 2019-07-25 Bristol-Myers Squibb Company Méthodes de traitement du cancer à l'aide d'anticorps dirigés contre tim3
AU2019210332A1 (en) 2018-01-22 2020-09-10 Pascal Biosciences Inc. Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
CN111629731A (zh) 2018-01-22 2020-09-04 百时美施贵宝公司 治疗癌症的组合物和方法
WO2019160904A1 (fr) 2018-02-15 2019-08-22 Macrogenics, Inc. Domaines variants de liaison à cd3 et leur utilisation en polythérapies pour le traitement d'une maladie
WO2019179421A1 (fr) * 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Nouvelles molécules d'anticorps pd-1/ctla-4 bispécifiques
WO2019179391A1 (fr) * 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Nouvelles molécules d'anticorps pd-1/ctla-4 bispécifiques
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
KR20200139724A (ko) 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
WO2019195452A1 (fr) 2018-04-04 2019-10-10 Bristol-Myers Squibb Company Anticorps anti-cd27 et leurs utilisations
BR112020026112A2 (pt) * 2018-06-21 2021-04-06 Shattuck Labs, Inc. Proteínas heterodiméricas e usos das mesmas
CN112739371A (zh) 2018-07-26 2021-04-30 百时美施贵宝公司 用于治疗癌症的lag-3组合疗法
CN109762068A (zh) * 2018-08-09 2019-05-17 源道隆（苏州）医学科技有限公司 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用
WO2020057610A1 (fr) * 2018-09-20 2020-03-26 Wuxi Biologics (Shanghai) Co., Ltd. Nouveaux complexes polypeptidiques anti-ctla-4/pd-1 bispécifiques
US20210395392A1 (en) 2018-10-09 2021-12-23 Bristol-Myers Squibb Company Anti-mertk antibodies for treating cancer
US20210338813A1 (en) 2018-10-19 2021-11-04 Bristol-Myers Squibb Company Combination Therapy for Melanoma
KR20210081384A (ko) 2018-10-23 2021-07-01 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
BR112021009111A2 (pt) 2018-11-16 2021-08-24 Bristol-Myers Squibb Company Anticorpos anti-nkg2a e usos dos mesmos
WO2020117992A1 (fr) * 2018-12-04 2020-06-11 The Broad Institute, Inc. Systèmes de vecteurs améliorés pour l'administration de protéine cas et de sgrna, et leurs utilisations
WO2020198672A1 (fr) 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Méthodes de traitement de tumeur
WO2020198676A1 (fr) 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Méthodes de traitement de tumeur
WO2020205516A1 (fr) * 2019-03-29 2020-10-08 Xencor, Inc. Dosage d'un anticorps bispécifique se liant à pd1 et ctla4
JP2022534967A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 多腫瘍遺伝子シグネチャーおよびその使用
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
KR20220016157A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 세포 국재화 시그너쳐 및 조합 요법
CN115340606B (zh) * 2019-05-31 2023-12-19 瑞阳(苏州)生物科技有限公司 与人lag-3蛋白结合的抗体及其编码基因和应用
WO2021007569A1 (fr) * 2019-07-11 2021-01-14 La Jolla Institute For Immunology Lymphocytes tfr intratumoraux réduisant l'efficacité du traitement anti-pd-1
CN112239506B (zh) * 2019-07-16 2023-09-26 复旦大学 一种抗PD-1及c-Met抗原的小分子双特异性抗体Diabody
EP4031873A1 (fr) 2019-09-22 2022-07-27 Bristol-Myers Squibb Company Profilage spatial quantitatif pour une thérapie par antagoniste de lag-3
AU2020353079A1 (en) 2019-09-25 2022-04-14 Bristol-Myers Squibb Company Composite biomarker for cancer therapy
EP4055392A1 (fr) 2019-11-05 2022-09-14 Bristol-Myers Squibb Company Dosages de protéine m et leurs utilisations
WO2021092220A1 (fr) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Procédés d'identification d'un sujet atteint d'une tumeur appropriée pour une thérapie par inhibiteur de point de contrôle
WO2021092221A1 (fr) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Procédés d'identification d'un sujet atteint d'une tumeur appropriée pour une thérapie par inhibiteur de point de contrôle
KR20220093349A (ko) 2019-11-08 2022-07-05 브리스톨-마이어스 스큅 컴퍼니 흑색종에 대한 lag-3 길항제 요법
WO2021097256A1 (fr) 2019-11-14 2021-05-20 Cohbar, Inc. Peptides antagonistes de cxcr4
US20230089255A1 (en) 2019-12-19 2023-03-23 Bristol-Myers Squibb Company Combinations of dgk inhibitors and checkpoint antagonists
WO2021133653A1 (fr) * 2019-12-23 2021-07-01 Macrogenics, Inc. Thérapie de traitement du cancer
CN115397859A (zh) 2020-01-30 2022-11-25 Ona疗法有限公司 治疗癌症和癌症转移的联合疗法
EP4100426A1 (fr) 2020-02-06 2022-12-14 Bristol-Myers Squibb Company Il-10 et ses utilisations
IL295979A (en) 2020-03-06 2022-10-01 Ona Therapeutics S L Anti-cd36 antibodies and their use for cancer treatment
KR20220157446A (ko) 2020-03-23 2022-11-29 브리스톨-마이어스 스큅 컴퍼니 암을 치료하기 위한 항-ccr8 항체
EP4146683A1 (fr) * 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. Protéines immunomodulatrices inhibitrices d'april et de baff et leurs procédés d'utilisation
JP2023116826A (ja) * 2020-05-20 2023-08-23 中外製薬株式会社 抗原結合分子
AU2021316192A1 (en) * 2020-07-27 2023-02-23 Macrogenics, Inc. Methods for the use of a PD-1 x CTLA-4 bispecific molecule
CN111944760A (zh) * 2020-08-14 2020-11-17 广东先康达生物科技有限公司 一种分泌双特异性抗体的免疫细胞及其应用
US20230265188A1 (en) 2020-08-28 2023-08-24 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
AU2021334361A1 (en) 2020-08-31 2023-05-11 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
JP2023544410A (ja) 2020-10-05 2023-10-23 ブリストル－マイヤーズ スクイブ カンパニー タンパク質を濃縮するための方法
WO2022087402A1 (fr) 2020-10-23 2022-04-28 Bristol-Myers Squibb Company Thérapie par antagoniste de lag-3 pour le cancer du poumon
CA3196535A1 (fr) 2020-10-28 2022-05-05 Alfredo C. Castro Combinaison d'inhibiteur d'ahr avec un inhibiteur de pdx ou de doxorubicine
WO2022120179A1 (fr) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Signatures géniques multi-tumorales et leurs utilisations
CA3196999A1 (fr) 2020-12-28 2022-07-07 Masano HUANG Methodes de traitement des tumeurs
US20220233693A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Antibody Compositions and Methods of Use Thereof
TW202246340A (zh) * 2021-03-05 2022-12-01 大陸商南京聖和藥業股份有限公司 抗ctla-4抗體及其應用
AU2022246593A1 (en) 2021-03-29 2023-10-12 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
WO2022212876A1 (fr) 2021-04-02 2022-10-06 The Regents Of The University Of California Anticorps dirigés contre un cdcp1 clivé et leurs utilisations
CA3226281A1 (fr) 2021-07-30 2023-02-02 ONA Therapeutics S.L. Anticorps anti-cd36 et leur utilisation pour traiter le cancer
CA3224890A1 (fr) 2021-10-29 2023-05-04 Bristol-Myers Squibb Company Therapie par antagoniste de lag-3 pour cancer hematologique
EP4215245A1 (fr) * 2022-01-19 2023-07-26 Innovative Cellular Therapeutics Holdings, Ltd. Cellules de récepteur d'antigène chimérique améliorées dans un microenvironnement tumoral hypoxique
WO2023147371A1 (fr) 2022-01-26 2023-08-03 Bristol-Myers Squibb Company Polythérapie pour carcinome hépatocellulaire
WO2023154784A1 (fr) * 2022-02-10 2023-08-17 Macrogenics, Inc. Méthodes d'utilisation d'un conjugué anticorps-médicament b7-h3 en association avec une molécule bispécifique pd-1 x ctla-4
WO2023164638A1 (fr) 2022-02-25 2023-08-31 Bristol-Myers Squibb Company Polythérapie pour carcinome colorectal
WO2023168404A1 (fr) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Méthodes de traitement d'une tumeur
WO2023170549A1 (fr) * 2022-03-07 2023-09-14 Medimmune Llc Procédés de traitement utilisant des anticorps bispécifiques ctla-4 et pd-1
WO2023170606A1 (fr) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Utilisation d'anticorps anti-claudine-1 pour augmenter la disponibilité des lymphocytes t
WO2023178329A1 (fr) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Procédés d'isolement de polypeptides
WO2023196987A1 (fr) 2022-04-07 2023-10-12 Bristol-Myers Squibb Company Méthodes de traitement d'une tumeur
WO2023196964A1 (fr) 2022-04-08 2023-10-12 Bristol-Myers Squibb Company Identification, classification, et quantification par apprentissage par machine de structures lymphoïdes tertiaires
WO2023235847A1 (fr) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Compositions d'anticorps et leurs procédés d'utilisation
EP4310197A1 (fr) 2022-07-21 2024-01-24 Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda Procédé pour identifier des patients atteints de cancer du poumon pour un traitement combiné d'immunothérapie et de chimiothérapie
WO2024069009A1 (fr) 2022-09-30 2024-04-04 Alentis Therapeutics Ag Traitement d'un carcinome hépatocellulaire résistant aux médicaments
WO2024114605A1 (fr) * 2022-11-29 2024-06-06 杭州阿诺生物医药科技有限公司 Polypeptide de fusion et son utilisation
WO2024116140A1 (fr) 2022-12-01 2024-06-06 Medimmune Limited Polythérapie comprenant des anticorps anti-pd-l1 et anti-cd73 pour le traitement du cancer

Family Cites Families (332)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985A (en) 1848-12-26 Pianoforte-action
US320A (en) 1837-07-31 John dainty
US3862925A (en) 1973-07-05 1975-01-28 American Home Prod Preparation of somatotropin release inhibiting factor and intermediates therefor
US3842067A (en) 1973-07-27 1974-10-15 American Home Prod Synthesis of(des-asn5)-srif and intermediates
JPS5726506B2 (fr) 1974-03-08 1982-06-04
US4105603A (en) 1977-03-28 1978-08-08 The Salk Institute For Biological Studies Peptides which effect release of hormones
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
EP0359096B1 (fr) 1988-09-15 1997-11-05 The Trustees Of Columbia University In The City Of New York Anticorps à contenu en carbohydrates modifié et méthodes pour leur préparation et utilisation
CA2018248A1 (fr) 1989-06-07 1990-12-07 Clyde W. Shearman Anticorps monoclonaux contre le recepteur alpha-beta de cellules t humaines, leur production et leur utilisation
WO1991003493A1 (fr) 1989-08-29 1991-03-21 The University Of Southampton CONJUGUES F(ab)3 ou F(ab)4 bi ou trispécifiques
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
CA2071867A1 (fr) 1989-11-06 1991-05-07 Edith Mathiowitz Mode de fabrication de microspheres proteiniques
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE4014524A1 (de) 1990-05-07 1991-11-14 Boehringer Mannheim Gmbh Typ ii - restriktionsendonuklease swai
FR2664500B1 (fr) 1990-07-13 1994-10-28 Lille Ii Universite Droit Sant Procede de preparation d'une lipoproteine modifiee par incorporation d'une substance active lipophile, lipoproteine modifiee ainsi obtenue et composition pharmaceutique ou cosmetique la contenant.
US5972337A (en) 1990-11-01 1999-10-26 Cancer Research Fund Of Contra Costa 46 kilodalton human milk fat globule (HMFG) antigen, fragments and fusion protein
AU666852B2 (en) 1991-05-01 1996-02-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5843749A (en) 1991-07-26 1998-12-01 Regeneron Pharmaceuticals, Inc. Ehk and Ror tyrosine kinases
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
IL108501A (en) 1994-01-31 1998-10-30 Mor Research Applic Ltd Antibodies and pharmaceutical compositions containing them
ATE352617T1 (de) 1994-05-06 2007-02-15 Roussy Inst Gustave Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
DE69630514D1 (de) 1995-01-05 2003-12-04 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
EP0850051A2 (fr) 1995-08-31 1998-07-01 Alkermes Controlled Therapeutics, Inc. Composition se pretant a la liberation prolongee d'un agent
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5942328A (en) 1996-02-29 1999-08-24 International Business Machines Corporation Low dielectric constant amorphous fluorinated carbon and method of preparation
PT885002E (pt) 1996-03-04 2011-07-14 Massachusetts Inst Technology Materiais e métodos para aumento da internalização celular
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
WO1998023289A1 (fr) 1996-11-27 1998-06-04 The General Hospital Corporation Modulation de la fixation de l'igg au fcrn
AU728911B2 (en) 1996-11-28 2001-01-18 Institut Gustave Roussy Mutants of the LAG-3 proteins, products for the expression of these mutants and use
DE69612501T2 (de) 1996-12-04 2001-10-25 Agfa Gevaert Nv Verfahren zur Herstellung eines durch Wärme erzeugten verbesserten Bildes
JP3884484B2 (ja) 1997-01-16 2007-02-21 マサチューセッツ インスティチュート オブ テクノロジー 吸入用粒子の調製
ATE427966T1 (de) 1997-02-11 2009-04-15 Immunomedics Inc Stimulation einer immunantwort durch antikírper, welche mit dem alpha-galaktosylepitop markiert sind
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0900841A1 (fr) 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Variantes d'épissure de LAG-3
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
DE69907456T2 (de) 1998-06-24 2004-03-25 Advanced Inhalation Research, Inc., Cambridge Grosse poröse partikel ausgestossen von einem inhalator
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
CZ303703B6 (cs) 1998-12-23 2013-03-20 Pfizer Inc. Monoklonální protilátka nebo její antigen-vázající fragment, farmaceutická kompozice obsahující tuto protilátku nebo fragment, bunecná linie produkující tuto protilátku nebo fragment, zpusob prípravy této protilátky, izolovaná nukleová kyselina kóduj
US20030190669A1 (en) 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
CN100340575C (zh) 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
DE60033293D1 (de) 1999-08-23 2007-03-22 Dana Farber Cancer Inst Inc Neue b7-4 moleküle und deren verwendungen
WO2001014557A1 (fr) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, recepteur de b7-4, et son utilisation
EP1792991A1 (fr) * 1999-08-24 2007-06-06 Medarex, Inc. Anticorps humains contre CTLA-4 et leur utilisation
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
AU784634B2 (en) 1999-11-30 2006-05-18 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US8414892B2 (en) 2000-10-18 2013-04-09 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US8501471B2 (en) 2000-10-18 2013-08-06 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US7737258B2 (en) 2000-10-18 2010-06-15 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US7666424B2 (en) 2001-10-17 2010-02-23 Sloan-Kettering Institute For Cancer Research Methods of preparing and using single chain anti-tumor antibodies
US7740845B2 (en) 2000-10-18 2010-06-22 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
WO2002086083A2 (fr) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Procedes d'amelioration de la capacite de reaction de cellules t
ATE524495T1 (de) 2001-07-31 2011-09-15 Ono Pharmaceutical Co Pd-1-spezifische substanz
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
DE60124912T2 (de) 2001-09-14 2007-06-14 Affimed Therapeutics Ag Multimerische, einzelkettige, Tandem-Fv-Antikörper
US20030138425A1 (en) 2001-09-21 2003-07-24 Mather Jennie Powell Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
JP4347694B2 (ja) 2001-10-16 2009-10-21 レイベン バイオテクノロジーズ，インコーポレイティド 癌関連抗原ｃｄ４６に結合する抗体およびその使用方法
WO2003035835A2 (fr) 2001-10-25 2003-05-01 Genentech, Inc. Compositions de glycoproteine
JP4488740B2 (ja) 2001-11-13 2010-06-23 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 免疫細胞活性化を調節する作用剤およびその使用方法
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP1492870A4 (fr) 2002-04-12 2005-08-03 Raven Biotechnologies Inc Anticorps se liant a l'integrine alpha-v-beta-6 et leurs methodes d'utilisation
MXPA04010092A (es) 2002-04-16 2004-12-13 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
WO2003093443A2 (fr) 2002-05-03 2003-11-13 Raven Biotechnologies, Inc. Alcam et modulateurs d'alcam
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
EP1513554B9 (fr) 2002-05-30 2011-11-09 Macrogenics, Inc. Proteines de liaison a cd16a et leur utilisation pour le traitement de troubles immunitaires
JP4488512B2 (ja) 2002-06-19 2010-06-23 レイベン バイオテクノロジーズ，インコーポレイティド 新規のｒａａｇ１０細胞表面標的および当該標的を認識する抗体ファミリー
ES2654064T3 (es) 2002-07-03 2024-03-13 Ono Pharmaceutical Co Composiciones inmunopotenciadoras que comprenden anticuerpos anti-PD-L1
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2505633A1 (fr) 2002-11-13 2004-05-27 Raven Biotechnologies, Inc. Antigene pipa et anticorps de liaison a celui-ci
EP1576014B1 (fr) 2002-12-23 2011-06-29 Wyeth LLC Anticorps anti pd-1 et leurs utilisations
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
CA2512729C (fr) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification et elaboration d'anticorps avec des regions du variant fc et procedes d'utilisation associes
EP1591527B1 (fr) 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specifique a pd-1 humain
AU2004217526B2 (en) 2003-02-28 2010-02-04 St. Jude Children's Research Hospital Inc. T cell regulation
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
PT1914314E (pt) 2003-07-07 2010-09-08 Scripps Research Inst Composições de pares ortogonais de lisil-arnt e aminoacil-arnt-sintetase e suas utilizações
WO2005019258A2 (fr) 2003-08-11 2005-03-03 Genentech, Inc. Compositions et methodes de traitement de maladies relatives au systeme immunitaire
CN101048425B (zh) 2003-09-18 2012-12-26 雷文生物技术公司 Kid3及与其结合的kid3抗体
WO2005047327A2 (fr) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
EP1709081B1 (fr) 2004-01-16 2011-04-06 Regeneron Pharmaceuticals, Inc. Polypeptides hybrides capables d'activer des recepteurs
WO2007046893A2 (fr) 2005-10-19 2007-04-26 Ibc Pharmaceuticals, Inc. Procedes et compositions permettant de produire des ensembles bioactifs de complexite augmentee et utilisations
KR20050082389A (ko) 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
AU2005250499B2 (en) 2004-06-03 2011-12-08 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
CN101432305B (zh) 2004-06-07 2014-07-30 雷文生物技术公司 运铁蛋白受体抗体
CA2570218C (fr) 2004-06-15 2015-11-10 The New York Blood Center, Inc. Propriete d'adjuvance et de stimulation des fonctions immunitaires de produits naturels de onchocerca volvulus
EP1919950A1 (fr) 2004-07-15 2008-05-14 Xencor, Inc. Variantes genetiques de fc optimisees
US20070166281A1 (en) 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
US20090123413A1 (en) 2004-08-23 2009-05-14 Britta Hardy Use of bat monoclonal antibody for immunotherapy
US20090252741A1 (en) 2004-09-08 2009-10-08 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
DE102004044786A1 (de) 2004-09-16 2006-04-06 Saurer Gmbh & Co. Kg Vorrichtung und Verfahren zum Ablegen eines Spinnkabels
US8087074B2 (en) 2004-10-15 2011-12-27 Symantec Corporation One time password
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
DE102004063494A1 (de) 2004-12-23 2006-07-13 Tegenero Ag Antikörper
EP1846767B1 (fr) 2005-01-12 2012-06-06 MacroGenics West, Inc. Antigène kid31 (carboxypeptidase m) et anticorps de liaison à celui-ci
US7847070B2 (en) 2005-01-31 2010-12-07 Raven Biotechnologies, Inc. LUCA2 and antibodies that bind thereto
WO2006084078A2 (fr) 2005-02-02 2006-08-10 Raven Biotechnologies, Inc. Antigene jam-3 et anticorps se liant a celui-ci
JP5328155B2 (ja) 2005-02-02 2013-10-30 マクロジェニックス ウエスト， インコーポレイテッド Ａｄａｍ−９モジュレータ
AU2006210606B2 (en) 2005-02-03 2012-03-22 Macrogenics West, Inc. Antibodies to Oncostatin M receptor
ZA200707275B (en) 2005-02-04 2009-01-28 Raven Biotechnologies Inc Antibodies that bind to EphA2 and methods of use thereof
AU2006232310B9 (en) 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
JP5011277B2 (ja) 2005-04-06 2012-08-29 アイビーシー・ファーマシューティカルズ・インコーポレーテッド ホモダイマー、ホモテトラマーまたはダイマーのダイマーのからなる安定に連結された複合体を発生させるための方法および使用
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
KR101339628B1 (ko) 2005-05-09 2013-12-09 메다렉스, 인코포레이티드 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
AU2006254902B8 (en) 2005-06-08 2012-08-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP1904530A2 (fr) 2005-07-07 2008-04-02 Coley Pharmaceutical Group, Inc. Polytherapie associant un anticorps anti-ctla-4 et un oligodesoxynucleotide synthetique a motif cpg destinee au traitement du cancer
WO2007021841A2 (fr) 2005-08-10 2007-02-22 Macrogenics, Inc. Identification et ingenierie d'anticorps presentant des zones de variants fc et procedes d'utilisation de ces anticorps
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1959993B1 (fr) 2005-12-16 2014-11-19 IBC Pharmaceuticals, Inc. Ensembles bio-actifs polyvalents a base d'immunoglobuline
CA2644903A1 (fr) 2006-03-10 2007-09-20 Macrogenics, Inc. Identification et modification genetique d'anticorps avec des chaines lourdes de variants et leurs procedes d'utilisation
EP1999154B1 (fr) 2006-03-24 2012-10-24 Merck Patent GmbH Domaines de proteine heterodimerique d'ingenierie
SG172698A1 (en) 2006-06-12 2011-07-28 Trubion Pharmaceuticals Inc Single-chain multivalent binding proteins with effector function
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AU2007281774A1 (en) 2006-08-04 2008-02-14 Astrazeneca Ab Human antibodies to ErbB 2
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
WO2008140603A2 (fr) 2006-12-08 2008-11-20 Macrogenics, Inc. MÉTHODES POUR LE TRAITEMENT DE MALADIE AU MOYEN D'IMMUNOGLOBULINES COMPRENANT DES RÉGIONS FC QUI PRÉSENTENT DES AFFINITÉS ALTÉRÉES POUR FCγR D'ACTIVATION ET FCγR D'INHIBITION
US8907065B2 (en) 2006-12-15 2014-12-09 Ablynx N.V. Polypeptides that modulate the interaction between cells of the immune system
MX351975B (es) 2006-12-27 2017-11-06 Emory Univ Star Composiciones y metodos para el tratamiento de infecciones y tumores.
JP2010523478A (ja) 2007-03-22 2010-07-15 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ モノクローナル抗体８ｈ９の使用
CA2682626A1 (fr) 2007-04-03 2008-10-09 Micromet Ag Elements de liaison bispecifiques specifiques d'especes croisees
EP1987839A1 (fr) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Anticorps monoclonal cytotoxique anti-LAG-3 et son utilisation pour le traitement ou la prévention d'un rejet de greffe d'organe et de maladies auto-immunes
EP4119579A1 (fr) 2007-05-31 2023-01-18 Genmab A/S Anticorps igg4 stables
JP2010190572A (ja) 2007-06-01 2010-09-02 Sapporo Medical Univ ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬
PL2170959T3 (pl) 2007-06-18 2014-03-31 Merck Sharp & Dohme Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
CN101821288A (zh) 2007-06-21 2010-09-01 宏观基因有限公司 共价双抗体及其用途
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
EP2626371A1 (fr) 2007-07-31 2013-08-14 MedImmune, LLC Protéines de liaison d'épitope multispécifique et leurs utilisations
US8062852B2 (en) 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
CA2706926A1 (fr) 2007-11-30 2009-06-11 Bristol-Myers Squibb Company Conjugues anticorps monoclonal-medicaments anti-b7h4 et procedes d'utilisation associes
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP3663318A1 (fr) 2008-01-07 2020-06-10 Amgen Inc. Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
EP2113255A1 (fr) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Immunoglobuline cytotoxique
US7565048B1 (en) 2008-05-30 2009-07-21 Ofs Fitel Llc Undersea optical fiber transmission systems
CA2726845C (fr) 2008-06-04 2017-09-26 Macrogenics, Inc. Anticorps a liaison alteree a fcrn et leurs procedes d'utilisation
US8460886B2 (en) 2008-07-04 2013-06-11 Ono Pharmaceutical Co., Ltd. Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human PD-1 antibody on cancers
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
PL2350129T3 (pl) 2008-08-25 2015-12-31 Amplimmune Inc Kompozycje antagonistów PD-1 i sposoby stosowania
WO2010027797A1 (fr) 2008-08-26 2010-03-11 Macrogenics Inc. Anticorps des récepteurs des lymphocytes t et leurs méthodes d’utilisation
WO2010028795A1 (fr) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Anticorps multivalents
WO2010028796A1 (fr) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Anticorps hexavalents trispécifiques
WO2010028797A1 (fr) 2008-09-10 2010-03-18 F. Hoffmann-La Roche Ag Anticorps multivalents
WO2010036959A2 (fr) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Anticorps anti-pd-1, pd-l1, et pd-l2 humains et leurs utilisations
EP2376109B1 (fr) 2008-12-19 2019-01-23 MacroGenics, Inc. Diabodies covalents et leurs utilisations
WO2010089411A2 (fr) 2009-02-09 2010-08-12 Universite De La Mediterranee Anticorps pd-1 et anticorps pd-l1 et leurs utilisations
EP2408817B1 (fr) 2009-03-20 2016-03-16 F.Hoffmann-La Roche Ag Anticorps anti-her di-spécifiques
JP2010249130A (ja) 2009-03-27 2010-11-04 Sanden Corp 流体機械
CN102448985B (zh) 2009-05-27 2015-08-05 霍夫曼-拉罗奇有限公司 三或四特异性抗体
US8277919B2 (en) 2009-07-23 2012-10-02 VMO Systems, Inc. Reflective coating for an optical disc
WO2011034660A1 (fr) 2009-09-16 2011-03-24 Immunomedics, Inc. Anticorps anti-cea de classe i et leurs utilisations
ES2672121T3 (es) 2009-10-07 2018-06-12 Macrogenics, Inc. Polipéptidos que contienen región Fc que presentan una función efectora mejorada debido a alteraciones del grado de fucosilación, y métodos para su uso
WO2011066389A1 (fr) 2009-11-24 2011-06-03 Medimmmune, Limited Agents de liaison ciblés dirigés contre b7-h1
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
US20110206672A1 (en) 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
PL2361936T3 (pl) 2010-02-25 2016-10-31 Cząsteczka wiążąca antygen i jej zastosowania
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
PE20170779A1 (es) 2010-03-04 2017-07-04 Macrogenics Inc Anticuerpos reactivos con b7-h3, fragmentos inmunologicamente activos de los mismos y usos de los mismos
US8993731B2 (en) 2010-03-11 2015-03-31 Ucb Biopharma Sprl PD-1 antibody
TWI426920B (zh) 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
SG10201800757TA (en) 2010-04-20 2018-02-27 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
US8876892B2 (en) 2010-04-21 2014-11-04 Medtronic, Inc. Prosthetic heart valve delivery system with spacing
TWI586806B (zh) 2010-04-23 2017-06-11 建南德克公司 異多聚體蛋白質之製造
CA2738352A1 (fr) 2010-04-28 2011-10-28 Mjsi, Inc. Adaptateur de chasse d'eau double debit a compensation
CA2797981C (fr) 2010-05-14 2019-04-23 Rinat Neuroscience Corporation Proteines heterodimeriques et leurs procedes de production et de purification
JP6320753B2 (ja) 2010-05-27 2018-05-09 ゲンマブ エー／エス Ｈｅｒ２に対するモノクローナル抗体
WO2011159877A2 (fr) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Anticorps di-spécifiques anti-tim-3 et pd-1 pour immunothérapie dans des états pathologiques immuns chroniques
EP3327035A1 (fr) 2010-06-22 2018-05-30 Precision Biologics Inc. Antigènes et anticorps spécifiques des cancers du côlon et du pancréas
WO2012009544A2 (fr) 2010-07-14 2012-01-19 Amgen Inc. Immunoglobuline à insertion de domaine
EP2601216B1 (fr) 2010-08-02 2018-01-03 MacroGenics, Inc. Di-anticorps covalents et utilisations associées
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
WO2013119903A1 (fr) 2012-02-10 2013-08-15 Research Corporation Technologies, Inc. Protéines de fusion comprenant des chaînes principales issues du domaine constant des immunoglobulines
JP5395824B2 (ja) 2011-02-16 2014-01-22 株式会社東芝 メモリシステム
KR20230005405A (ko) * 2011-02-25 2023-01-09 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
JP6014116B2 (ja) 2011-03-31 2016-10-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ヒト・プログラム死受容体ｐｄ−１に対する抗体の安定製剤および関連治療
WO2012145493A1 (fr) 2011-04-20 2012-10-26 Amplimmune, Inc. Anticorps et autres molécules qui se lient à b7-h1 et à pd-1
WO2012143524A2 (fr) 2011-04-20 2012-10-26 Genmab A/S Anticorps bispécifiques contre her2 et cd3
KR102030987B1 (ko) 2011-04-25 2019-11-11 다이이찌 산쿄 가부시키가이샤 항 ｂ７-ｈ３항체
US9750806B2 (en) 2011-05-17 2017-09-05 Trion Research Gmbh Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties
PT2714733T (pt) 2011-05-21 2019-05-23 Macrogenics Inc Moléculas de ligação a cd3 com capacidade para ligar a cd3 humana e não humana
WO2012162068A2 (fr) 2011-05-21 2012-11-29 Macrogenics, Inc. Domaines de liaison du sérum déimmunisé et leur utilisation pour prolonger la demi-vie du sérum
WO2012162583A1 (fr) 2011-05-26 2012-11-29 Ibc Pharmaceuticals, Inc. Conception et construction de nouveaux anticorps multivalents
WO2013003652A1 (fr) 2011-06-28 2013-01-03 Sea Lane Biotechnologies, Llc Protéines de liaison à domaines variables empilés polyvalentes
ES2694749T3 (es) 2011-06-30 2018-12-27 Genzyme Corporation Inhibidores de la activación de células T
WO2013006544A1 (fr) 2011-07-06 2013-01-10 Medimmune, Llc Procédé de préparation de polypeptides multimères
US9920438B2 (en) 2011-07-07 2018-03-20 Massachusetts Institute Of Technology Methods and apparatus for ultrathin catalyst layer for photoelectrode
US20140242081A1 (en) 2011-07-18 2014-08-28 Micromet Ag Dosing regimens for treatment of cea-expressing cancers
CN103687879B (zh) 2011-07-22 2016-05-04 阿菲姆德农业医药公司 多价抗原结合fv分子
EP2734551B1 (fr) 2011-07-24 2018-01-10 Cure Tech Ltd. Variants d'anticorps monoclonaux immunomodulateurs humanisés
EP2742953B1 (fr) 2011-08-11 2021-09-22 ONO Pharmaceutical Co., Ltd. Agent thérapeutique destiné à des maladies auto-immunes comprenant un agoniste de pd-1
JP2014533929A (ja) 2011-09-23 2014-12-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー ５ｔ４およびｃｄ３に対する二重特異的結合性分子
EP2771361A1 (fr) 2011-10-24 2014-09-03 AbbVie Inc. Agents de liaison immunologique bispécifiques contre le tnf et l'il-17
SG10201805291TA (en) 2011-10-27 2018-08-30 Genmab As Production of heterodimeric proteins
WO2013070565A1 (fr) 2011-11-07 2013-05-16 Medimmune, Llc Protéines de liaison multispécifiques et multivalentes et leurs utilisations
WO2013163427A1 (fr) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Anticorps pour traiter les infections par le vih-1
US20150065690A1 (en) 2012-04-27 2015-03-05 Bioatla, Llc Modified antibody regions and uses thereof
RU2671465C2 (ru) 2012-05-11 2018-10-31 Медиммьюн Лимитед Варианты ctla-4
CN104470949A (zh) 2012-05-15 2015-03-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
MX2014014162A (es) 2012-05-24 2015-02-04 Hoffmann La Roche Anticuerpos multiespecificos.
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
EP2890715B1 (fr) 2012-08-03 2020-12-16 Dana-Farber Cancer Institute, Inc. Anticorps de liaison double à agent unique anti-pd-l1 et pd-l2 et procédés d'utilisation
US10457733B2 (en) 2012-08-03 2019-10-29 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
WO2014043708A1 (fr) 2012-09-17 2014-03-20 Traber Peter G Procédé pour l'amélioration d'immunothérapies spécifiques dans le traitement du cancer
NZ631405A (en) 2012-10-02 2017-01-27 Bristol Myers Squibb Co Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
BR112015008118A2 (pt) 2012-10-12 2017-12-05 Brigham & Womens Hospital Inc reforço da resposta imune
EP2912063A1 (fr) 2012-10-23 2015-09-02 Bristol-Myers Squibb Company Association d'anticorps anti-kir et anti-ctla-4 pour le traitement du cancer
EP2911669B1 (fr) 2012-10-26 2024-04-10 The University of Chicago Combinaison synergique d'inhibiteurs immunologiques pour le traitement du cancer
CA2890256A1 (fr) 2012-11-07 2014-05-15 Pfizer Inc. Anticorps anti-recepteur alpha 2 de l'il-13 et conjugues anticorps-medicaments
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
RU2662991C2 (ru) 2013-03-12 2018-07-31 Биокон Лтд. Слитые иммуномодулирующие белки и способы их получения
PL2970473T3 (pl) 2013-03-14 2018-01-31 Bristol Myers Squibb Co Kombinacja agonisty dr5 i antagonisty anty-pd-1 oraz metody stosowania
RU2020115527A (ru) 2013-03-14 2020-07-07 Макродженикс, Инк. Биспецифичные молекулы, иммунореактивные с иммунными эффекторными клетками, экспрессирующими активирующий рецептор
CN105209494B (zh) 2013-03-15 2019-04-09 葛兰素史克知识产权开发有限公司 抗lag-3结合蛋白
EP3770176A1 (fr) 2013-05-02 2021-01-27 AnaptysBio, Inc. Anticorps dirigés contre la protéine de mort programmée 1 (pd-1)
CA3175360C (fr) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Proteines de liaison a l'antigene qui se lient a pd-1
WO2014209804A1 (fr) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Anticorps bispécifiques
DK177790B1 (en) 2013-08-08 2014-07-07 Liqtech Internat A S A METHOD OF PRODUCING A CERAMIC FILTER MEMBRANE, A METHOD OF IMPROVING A CERAMIC FILTER MEMBRANE AND THE CERAMIC FILTER MEMBRANE OBTAINED BY THE METHOD
WO2015026634A1 (fr) 2013-08-20 2015-02-26 Merck Sharp & Dohme Corp. Traitement du cancer avec une combinaison d'un antagoniste de pd-1 et du dinaciclib
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
EP2840091A1 (fr) 2013-08-23 2015-02-25 MacroGenics, Inc. Diabody se liant specifiquement a l'antigene gpA33 et CD3 et procedes d'utilisation
EP2839842A1 (fr) 2013-08-23 2015-02-25 MacroGenics, Inc. Bianticorps monovalents bi-spécifiques capables de se lier aux CD123 et CD3 et leurs utilisations
WO2015036394A1 (fr) 2013-09-10 2015-03-19 Medimmune Limited Anticorps contre pd-1 et leurs utilisations
PT3702373T (pt) 2013-09-13 2022-09-27 Beigene Switzerland Gmbh Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico
EP3178849B1 (fr) 2013-09-20 2019-03-20 Bristol-Myers Squibb Company Combinaison d'anticorps anti-lag-3 et d'anticorps anti-pd-1 pour traiter des tumeurs
WO2015048312A1 (fr) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Méthodes de traitement de cancers hématologiques
WO2015088930A1 (fr) 2013-12-10 2015-06-18 Merck Sharp & Dohme Corp. Dosage de proximité immunohistochimique pour cellules positives pd-1 et cellules positives de ligand pd dans un tissu tumoral
JP6502959B2 (ja) 2013-12-12 2019-04-17 上海恒瑞医薬有限公司 Ｐｄ−１抗体、その抗原結合性断片及びそれらの医学的使用
PT3083689T (pt) 2013-12-17 2020-08-27 Genentech Inc Anticorpos anti-cd3 e métodos de utilização
WO2015094992A1 (fr) 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Biomarqueurs de signature du gène ifn-gamma de la réponse tumorale à des antagonistes de pd-1
EP3083692B1 (fr) 2013-12-17 2020-02-19 F.Hoffmann-La Roche Ag Méthode de traitement des cancers utilisant des antagonists se liant à l'axe pd-1 et des taxanes
CA2931641C (fr) 2013-12-30 2022-05-10 Epimab Biotherapeutics Inc. Fabs d'immunoglobuline en tandem et leurs utilisations
WO2015112534A2 (fr) 2014-01-21 2015-07-30 Medimmune, Llc Compositions et procédés pour moduler et réorienter des réponses immunitaires
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
EA201691361A1 (ru) 2014-01-28 2016-12-30 Бристол-Маерс Сквибб Компани Антитела к lag-3 для лечения гематологических злокачественных опухолей
MX2016010082A (es) 2014-02-04 2016-10-07 Pfizer Combinacion de un antagonista de proteina de muerte programada 1 (pd-1) y un inhibidor del receptor del factor de crecimiento endotelial vascular (vegfr) para tratar cancer.
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
CN104974253A (zh) * 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 抗ctla-4/pd-1双特异性抗体、其制备方法及应用
US20150307620A1 (en) 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
JP2017515859A (ja) 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
EP3954703A3 (fr) * 2014-05-29 2022-05-18 MacroGenics, Inc. Molécules de liaison trispécifiques et leurs procédés d'utilisation
WO2015195163A1 (fr) 2014-06-20 2015-12-23 R-Pharm Overseas, Inc. Anticorps totalement humain anti-pd-l1
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
WO2015200828A1 (fr) 2014-06-27 2015-12-30 H. Lee Moffit Cancer Center And Research Institute, Inc. Conjugués pour immunothérapie
NZ766356A (en) 2014-07-22 2024-02-23 Cb Therapeutics Inc Anti-pd-1 antibodies
CN105330740B (zh) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
SG11201700672YA (en) 2014-08-05 2017-02-27 MabQuest SA Immunological reagents binding to pd-1
NZ766660A (en) 2014-08-05 2024-02-23 Cb Therapeutics Inc Anti-pd-l1 antibodies
CR20170096A (es) 2014-08-12 2017-06-15 Alligator Bioscience Ab Tratamientos conjuntos con anticuerpos anti cd40
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
SG11201701599UA (en) 2014-09-05 2017-03-30 Janssen Pharmaceutica Nv Cd123 binding agents and uses thereof
TWI706960B (zh) 2014-09-26 2020-10-11 美商宏觀基因股份有限公司 能夠結合cd19和cd3的雙特異性雙抗體及其用途
AU2015323860B2 (en) 2014-09-29 2021-05-27 Duke University Bispecific molecules comprising an HIV-1 envelope targeting arm
ES2774448T3 (es) 2014-10-03 2020-07-21 Novartis Ag Terapias de combinación
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
BR112017008914A2 (pt) 2014-10-29 2018-01-16 Five Prime Therapeutics, Inc. método para tratar câncer, composição e uso da composição
EP3218409A2 (fr) 2014-11-11 2017-09-20 Sutro Biopharma, Inc. Anticorps anti-pd-1, compositions comprenant des anticorps anti-pd-1 et procédés d'utilisation d'anticorps anti-pd-1
AU2015348657B2 (en) 2014-11-20 2021-06-10 F. Hoffmann-La Roche Ag Combination therapy of T cell activating bispecific antigen binding molecules CD3 ABD folate receptor 1 (FolRl) and PD-1 axis binding antagonists
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
CA2971734A1 (fr) 2014-12-22 2016-06-30 Enumeral Biomedical Holdings, Inc. Anticorps anti-pd-1
WO2016115274A1 (fr) 2015-01-14 2016-07-21 Compass Therapeutics Llc Constructions de liaison à des antigènes immunomodulateurs multispécifiques
JP2018506280A (ja) 2015-02-06 2018-03-08 カドモン コーポレイション，リミティド ライアビリティ カンパニー 免疫調節薬
US20160304607A1 (en) 2015-04-17 2016-10-20 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-pd-1 antibody and another antibody
CN104987421A (zh) * 2015-05-13 2015-10-21 北京比洋生物技术有限公司 抗ctla-4和pd-1的双重可变结构域免疫球蛋白
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
TW201709929A (zh) 2015-06-12 2017-03-16 宏觀基因股份有限公司 治療癌症的聯合療法
WO2017011413A1 (fr) 2015-07-10 2017-01-19 Duke University Molécules bispécifiques comprenant un bras dirigé contre l'enveloppe du vih-1
WO2017011414A1 (fr) 2015-07-10 2017-01-19 Duke University Molécules bispécifiques comprenant un bras dirigé contre l'enveloppe du vih-1
IL297090A (en) * 2015-07-30 2022-12-01 Macrogenics Inc Molecules that bind pd-1 and methods of using them
AU2016307955A1 (en) 2015-08-17 2018-03-08 Macrogenics, Inc. Bispecific monovalent diabodies that are capable of binding B7-H3 and CD3, and uses thereof
RU2731202C2 (ru) 2015-10-08 2020-08-31 Макродженикс, Инк. Комбинированная терапия для лечения рака
EP3370768B9 (fr) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Anticorps se liant spécifiquement à pd-1 et leurs utilisations
TW202208440A (zh) 2015-12-14 2022-03-01 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
JP2019514889A (ja) 2016-04-25 2019-06-06 メディミューン，エルエルシー 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
AU2017278325A1 (en) 2016-06-07 2019-01-24 Macrogenics, Inc. Combination therapy
MX2019003225A (es) 2016-09-21 2019-06-10 Aptevo Res & Development Llc Proteínas de unión a cd123 y composiciones y métodos relacionados.
JP7106538B2 (ja) 2016-12-07 2022-07-26 アジェナス インコーポレイテッド 抗体およびその使用方法

Also Published As

Publication number Publication date
HK1255039A1 (zh) 2019-08-02
US20210130470A1 (en) 2021-05-06
BR112018011781A2 (pt) 2018-12-04
JP2019506444A (ja) 2019-03-07
GEP20217328B (en) 2021-12-10
ECSP18043564A (es) 2018-06-30
JP2022001584A (ja) 2022-01-06
MY196756A (en) 2023-05-03
WO2017106061A1 (fr) 2017-06-22
AR107781A1 (es) 2018-06-06
EA201891178A1 (ru) 2019-01-31
CL2018001545A1 (es) 2018-10-05
AU2016370376B2 (en) 2023-12-14
TWI758267B (zh) 2022-03-21
IL260021B (en) 2022-09-01
CN108367069B (zh) 2022-08-23
JP6955507B2 (ja) 2021-10-27
US20190161548A1 (en) 2019-05-30
CO2018005932A2 (es) 2018-06-20
MX2018007089A (es) 2019-01-30
AU2016370376A1 (en) 2018-06-21
CR20180318A (es) 2018-09-19
CN108367069A (zh) 2018-08-03
US20240084015A1 (en) 2024-03-14
US11840571B2 (en) 2023-12-12
TW201725215A (zh) 2017-07-16
ZA201803472B (en) 2019-01-30
EP3389714A1 (fr) 2018-10-24
US10954301B2 (en) 2021-03-23
EP3389714A4 (fr) 2019-11-13
IL260021A (en) 2018-07-31
UA125611C2 (uk) 2022-05-04
CA3006462A1 (fr) 2017-06-22
TW202208440A (zh) 2022-03-01
KR20180086250A (ko) 2018-07-30
PH12018501220A1 (en) 2019-01-28
KR102424513B1 (ko) 2022-07-25
SG11201804839WA (en) 2018-07-30
AU2024201607A1 (en) 2024-04-11
CA3006462C (fr) 2023-10-31

Similar Documents

Publication Publication Date Title
MA44082A (fr) Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
IL287848A (en) Multispecific antigen binding molecules and their uses
SMT201600392B (it) Anticorpi bispecifici diretti contro cd3epsilon e bcma
MA42665A (fr) Dianticorps monovalents bispécifiques capables de se lier à b7-h3 et à cd3 et leurs utilisations
MA42935A (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
DK3539059T3 (da) Udførelse af kernel striding i hardware
DK3456346T3 (da) Pd-1- og lag-3-bindingsmolekyler og fremgangsmåder til anvendelse deraf
DK3411402T3 (da) Bcma- og cd3-bispecifikke t-celle-engagerende antistofkonstruktioner
DK3789402T3 (da) Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler og PD-1-aksebindende antagonister
DK3430141T3 (da) Oligonukleotider til reduktion af PD-L1-ekspression
DK3334824T3 (da) Pd-1-antistoffer
DK3380522T3 (da) Antistofmolekyler til april og anvendelser deraf
DK3256468T3 (da) Tricykliske forbindelser og anvendelser deraf i lægemidler
MA40737A (fr) Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
DK3242685T3 (da) Cxcr4-bindende molekyler
IL259729A (en) Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
MA43141A (fr) Nouveaux composés et leurs utilisations
DK3394131T3 (da) Strålehærdbare urethan(meth)acrylater med resterende isocyanatgrupper
DK3390364T3 (da) Små molekyler til hæmning af kemokinaktivitet og/eller cancercellevækst
IT201600118957A1 (it) Struttura di fissaggio di componente di bicicletta e assemblaggio di componente di bicicletta
ITUB20152949A1 (it) Impianto e metodo di degasaggio sottovuoto dell?acciaio liquido
MA43704A (fr) Liraglutide dans des états cardio-vasculaires
DK3289095T5 (da) Detektering af nukleinsyremolekyler
FR3051700B1 (fr) Ensemble de soudage notamment de goujons
DK3221865T3 (da) Fotonneutralisator og neutralstråleinjektor med samme